omeprazole has been researched along with Gastric Fistula in 13 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Gastric Fistula: Abnormal passage communicating with the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The healing rate of gastrocutaneous fistula in rat (2-mm-diameter stomach defect, 3-mm-diameter skin defect) validates macro/microscopically and biomechanically a direct skin wound/stomach ulcer relation, and identifies a potential therapy consisting of: (i) stable gastric pentadecapeptide BPC 157 [in drinking water (10 microg/kg) (12 ml/rat/day) or intraperitoneally (10 microg/kg, 10 ng/kg, 10 pg/kg)], (ii) atropine (10 mg/kg), ranitidine (50 mg/kg), and omeprazole (50 mg/kg), (iii) 6-alpha-methylprednisolone (1 mg/kg) [intraperitoneally, once daily, first application at 30 min following surgery; last 24 h before sacrifice (at postoperative days 1, 2, 3, 7, 14, and 21)]." | 7.75 | Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. ( Anic, T; Batelja, L; Berkopic, L; Blagaic Boban, A; Brcic, L; Cesarec, V; Coric, M; Dolovski, Z; Drmic, D; Ilic, S; Ivica, M; Klicek, R; Kocman, I; Kolenc, D; Lovric Bencic, M; Mise, S; Radic, B; Seiwerth, S; Sever, M; Sikiric, P; Skorjanec, S; Staresinic, M; Tonkic, A; Zoricic, I, 2009) |
| "The duration of intragastric pH-elevation upon administration of the novel H+K(+)-ATPase inhibitor pantoprazole and its pharmacodynamic interaction with H2 receptor blockade was assessed in the gastric fistula dog using the intragastric 24 hour pH-metry." | 7.68 | The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. ( Bräuer, U; Kromer, W; Postius, S, 1991) |
| " In experiments on conscious rats with chronic gastric fistula as well as on anesthetized animals it was demonstrated that luminal infusion of acidic hyperosmotic solution of NaCl enhances basal secretions of bicarbonates and pepsinogen that was fully blocked by indomethacin." | 3.78 | [Effect of mild irritants on gastric outputs of bicarbonates and pepsinogen depends on the rate of acid secretion]. ( Andreeva, IuV; Khropycheva, RP; Zolotarev, VA, 2012) |
| "The healing rate of gastrocutaneous fistula in rat (2-mm-diameter stomach defect, 3-mm-diameter skin defect) validates macro/microscopically and biomechanically a direct skin wound/stomach ulcer relation, and identifies a potential therapy consisting of: (i) stable gastric pentadecapeptide BPC 157 [in drinking water (10 microg/kg) (12 ml/rat/day) or intraperitoneally (10 microg/kg, 10 ng/kg, 10 pg/kg)], (ii) atropine (10 mg/kg), ranitidine (50 mg/kg), and omeprazole (50 mg/kg), (iii) 6-alpha-methylprednisolone (1 mg/kg) [intraperitoneally, once daily, first application at 30 min following surgery; last 24 h before sacrifice (at postoperative days 1, 2, 3, 7, 14, and 21)]." | 3.75 | Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. ( Anic, T; Batelja, L; Berkopic, L; Blagaic Boban, A; Brcic, L; Cesarec, V; Coric, M; Dolovski, Z; Drmic, D; Ilic, S; Ivica, M; Klicek, R; Kocman, I; Kolenc, D; Lovric Bencic, M; Mise, S; Radic, B; Seiwerth, S; Sever, M; Sikiric, P; Skorjanec, S; Staresinic, M; Tonkic, A; Zoricic, I, 2009) |
| " CR 2945 was about as efficacious as ranitidine against the indomethacin- and ethanol-induced gastric ulcers and the cysteamine-induced duodenal ulcer in rats." | 3.70 | Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. ( Impicciatore, M; Letari, O; Makovec, F; Mennuni, L; Revel, L, 1999) |
| "The duration of intragastric pH-elevation upon administration of the novel H+K(+)-ATPase inhibitor pantoprazole and its pharmacodynamic interaction with H2 receptor blockade was assessed in the gastric fistula dog using the intragastric 24 hour pH-metry." | 3.68 | The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. ( Bräuer, U; Kromer, W; Postius, S, 1991) |
| "Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically." | 1.33 | Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. ( Cao, H; Hu, ZQ; Ikejima, T; Sun, LX; Wang, MW; Zhao, WH, 2005) |
| " In this model, duration of action studies showed that significant residual inhibition of acid secretion remained 8 hours after intravenous dosing with SK&F 97574 (producing peak inhibition of 92%)." | 1.29 | Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties. ( Ife, RJ; Leach, C; Parsons, ME; Pope, AJ; Postius, S; Rasmussen, TC; Rushant, B, 1995) |
| "Pretreatment with omeprazole (15 mumol/kg) to suppress gastric acid secretion or with L-364,718 (5 mumol/kg) to antagonize CCK receptors in the diverted state, resulted in the decline in pancreatic secretion similar to that observed after opening the GF." | 1.28 | Feedback control of pancreatic secretion in rats. Role of gastric acid secretion. ( Bilski, J; Konturek, PK; Konturek, SJ; Krzyzek, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mansur Reimão, S | 1 |
| Ferreira De Souza, T | 1 |
| Otoch, JP | 1 |
| Makoto Sakai, C | 1 |
| Yance Hurtado, RM | 1 |
| Menezes Marques, L | 1 |
| Guimarães Hourneaux De Moura, E | 1 |
| Artifon, EL | 1 |
| Skorjanec, S | 1 |
| Dolovski, Z | 1 |
| Kocman, I | 1 |
| Brcic, L | 1 |
| Blagaic Boban, A | 1 |
| Batelja, L | 1 |
| Coric, M | 1 |
| Sever, M | 1 |
| Klicek, R | 1 |
| Berkopic, L | 1 |
| Radic, B | 1 |
| Drmic, D | 1 |
| Kolenc, D | 1 |
| Ilic, S | 1 |
| Cesarec, V | 1 |
| Tonkic, A | 1 |
| Zoricic, I | 1 |
| Mise, S | 1 |
| Staresinic, M | 1 |
| Ivica, M | 1 |
| Lovric Bencic, M | 1 |
| Anic, T | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Zolotarev, VA | 1 |
| Andreeva, IuV | 1 |
| Khropycheva, RP | 1 |
| Cao, H | 1 |
| Wang, MW | 1 |
| Sun, LX | 1 |
| Ikejima, T | 1 |
| Hu, ZQ | 1 |
| Zhao, WH | 1 |
| Konturek, SJ | 2 |
| Brzozowski, T | 1 |
| Radecki, T | 1 |
| Parsons, ME | 1 |
| Rushant, B | 1 |
| Rasmussen, TC | 1 |
| Leach, C | 1 |
| Ife, RJ | 1 |
| Postius, S | 2 |
| Pope, AJ | 1 |
| Kinoshita, M | 1 |
| Saito, N | 1 |
| Tamaki, H | 1 |
| Makovec, F | 1 |
| Revel, L | 1 |
| Letari, O | 1 |
| Mennuni, L | 1 |
| Impicciatore, M | 1 |
| Uchiyama, K | 1 |
| Wakatsuki, D | 1 |
| Kakinoki, B | 1 |
| Takeuchi, Y | 1 |
| Araki, T | 1 |
| Morinaka, Y | 1 |
| Lee, M | 1 |
| Aldred, K | 1 |
| Lee, E | 1 |
| Prince, MD | 1 |
| Feldman, M | 1 |
| Bilski, J | 1 |
| Konturek, PK | 1 |
| Krzyzek, E | 1 |
| Deruyter, L | 1 |
| Van Blerk, M | 1 |
| Cadière, GB | 1 |
| De Graef, J | 1 |
| Willems, G | 1 |
| Bräuer, U | 1 |
| Kromer, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for omeprazole and Gastric Fistula
| Article | Year |
|---|---|
Double pylorus in the era of proton pump inhibitors.
Topics: Gastric Fistula; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Pylorus | 2014 |
Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole.
Topics: Adrenal Cortex Hormones; Animals; Anti-Ulcer Agents; Atropine; Cutaneous Fistula; Disease Models, An | 2009 |
[Effect of mild irritants on gastric outputs of bicarbonates and pepsinogen depends on the rate of acid secretion].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bicarbonates; Biological Transp | 2012 |
Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pe | 2005 |
Protective action of omeprazole, a benzimidazole derivative, on gastric mucosal damage by aspirin and ethanol in rats.
Topics: Animals; Aspirin; Benzimidazoles; Dose-Response Relationship, Drug; Epoprostenol; Ethanol; Female; G | 1983 |
Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Topics: Aminoquinolines; Animals; Antacids; Binding, Competitive; Dogs; Dose-Response Relationship, Drug; En | 1995 |
Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, Peptic; Gastric Acid; Gastric Fistula; G | 1997 |
Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
Topics: Animals; Anti-Anxiety Agents; Anti-Ulcer Agents; Benzodiazepines; Benzodiazepinones; Calcium; Cats; | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carba | 1999 |
Importance of gastric acid in gastric ulcer formation in rabbits with antibody-induced prostaglandin deficiency.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Antibodies; Cross Reactions; Gastric Ac | 1992 |
Feedback control of pancreatic secretion in rats. Role of gastric acid secretion.
Topics: Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Esters; Feedback; Gabexate; Gastric Acid; G | 1992 |
Treatment of high-output gastric fistulas with omeprazole.
Topics: Gastric Fistula; Humans; Male; Middle Aged; Omeprazole; Recurrence | 1991 |
The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Dogs; F | 1991 |